Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tabelecleucel

Allogeneic cytotoxic T lymphocytes (CTLs) selective for the tumor-associated antigens (TAAs) expressed by the Epstein-Barr virus (EBV), with potential immunostimulating and antineoplastic activities. Upon administration, and after hematopoietic cell transplants (HCT) or solid organ transplants (SOT), or during certain other immunocompromised states, tabelecleucel targets and binds to EBV-associated antigens expressed on EBV-infected cells. This results in lysis of EBV-infected cells and prevents growth of EBV-associated cancer cells. EBV is associated with a variety of cancers and post-transplant lymphoproliferative disorders (EBV+ PTLD).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic EBV-specific CTLs ATA129
allogeneic EBV-specific cytotoxic T lymphocytes
allogeneic EBV-specific cytotoxic T lymphocytes
CTLs ATA129
US brand name:Tab-cel
Teb-cel
Foreign brand name:Ebvallo
Abbreviation:EBV-CTLs
Code name:ATA 129
ATA129
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search